Quetiapine monotherapy in the treatment of patients with bipolar I or II depression and a rapid‐cycling disease course: a randomized, double‐blind, placebo‐controlled study
Authors:
- E VietaE Vieta
- for the BOLDER Study GroupFGfor the BOLDER Study Group
- 1 June 2007
- journal article
- research article
- Published by Wiley in Bipolar Disorders
- Vol. 9 (4) , 413-425
Abstract
Objectives: To investigate the efficacy and tolerability of quetiapine monotherapy in patients with bipolar I or II disorder with a rapid‐cycling disease course.Methods: Adult patients with a DSM‐IV diagnosis of bipolar disorder, most recent episode depressed, with a rapid‐cycling disease course from a previously completed multicenter trial randomized to 8 weeks of treatment with quetiapine 600 mg/day (n = 31), quetiapine 300 mg/day (n = 42), or placebo (n = 35) were included in this sub‐analysis. The primary efficacy variable was change from baseline to week 8 in Montgomery–Asberg Depression Rating Scale (MADRS) total score.Results: Quetiapine (600 and 300 mg/day) provided significantly greater mean reductions from baseline to week 8 in the MADRS total score than placebo (−21.1, −20.7 versus −11.6, both p < 0.001) in this patient population. Effect sizes in patients with a rapid‐cycling disease course were 1.2 (600 mg/day) and 1.1 (300 mg/day) and were similar for bipolar I (0.98 and 1.22) and bipolar II (1.45 and 0.97) sub‐groups. Significant improvements were also noted on the Clinical Global Impression, Hamilton Rating Scale for Depression, Hamilton Rating Scale for Anxiety, Pittsburgh Sleep Quality Index, and Quality of Life Enjoyment and Satisfaction Questionnaire scales. Quetiapine was generally well tolerated with moderate increases in weight and extrapyramidal side effects compared to placebo. The incidence of treatment‐emergent mania was similar to placebo.Conclusions: Quetiapine monotherapy (600 or 300 mg/day) is clinically effective and well tolerated in the short‐term treatment of depressive episodes in patients with bipolar I or II disorder who have a rapid‐cycling disease course.Keywords
This publication has 39 references indexed in Scilit:
- A 20-Month, Double-Blind, Maintenance Trial of Lithium Versus Divalproex in Rapid-Cycling Bipolar DisorderAmerican Journal of Psychiatry, 2005
- A Randomized, Double-Blind, Placebo-Controlled Trial of Quetiapine in the Treatment of Bipolar I or II DepressionAmerican Journal of Psychiatry, 2005
- Rapid cycling bipolar disorder: historical overview and focus on emerging treatmentsBipolar Disorders, 2004
- Response to clozapine of rapid cycling versus non‐cycling patients with a history of maniaBipolar Disorders, 2004
- Rapid and Non-Rapid Cycling Bipolar DisorderThe Journal of Clinical Psychiatry, 2003
- A New Depression Scale Designed to be Sensitive to ChangeThe British Journal of Psychiatry, 1979
- A Rating Scale for Mania: Reliability, Validity and SensitivityThe British Journal of Psychiatry, 1978
- A RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTSActa Psychiatrica Scandinavica, 1970
- A RATING SCALE FOR DEPRESSIONJournal of Neurology, Neurosurgery & Psychiatry, 1960
- THE ASSESSMENT OF ANXIETY STATES BY RATINGPsychology and Psychotherapy: Theory, Research and Practice, 1959